---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-22-000103"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T07:59:37.331593+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q3 net loss narrows to $24.8M; receives $60M Gilead upfront; cash runway into mid-2024

## Summary
- Q3 total revenue $41.7M (up from $15.7M YoY) including $30M Incyte milestone and $4.4M MARGENZA sales.
- Net loss $24.8M ($0.40/share) vs $52.9M ($0.86/share) in Q3 2021; R&D spend $48.2M.
- Cash $123.6M at Sep 30, plus $60M from Gilead in Oct; cash runway extended into mid-2024.
- Gilead collaboration for MGD024 and up to two bispecific programs; potential $1.7B in milestones plus tiered royalties.
- Teplizumab PDUFA date Nov 17, 2022; if approved, MacroGenics eligible for $60M milestone from Provention Bio.

## SEC filing metadata
- accession: 0001125345-22-000103
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/0001125345-22-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/mgnx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-22-000103
- JSON: https://secwatch.observer/filing/0001125345-22-000103.json
- Plain text: https://secwatch.observer/filing/0001125345-22-000103.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported the quarter ended September 30, 2022 results: revenue $41.7 million.
  - Period: the quarter ended September 30, 2022
  - Revenue: $41.7 million
  - Result: reported results
  source text: Total revenue, consisting primarily of revenue from collaborative agreements, was $41.7 million for the quarter ended September 30, 2022, compared to total revenue of $15.7 million for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000103/0001125345-22-000103-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.